首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准

智通财经07-16 16:38

【首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】首药控股公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651417551?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-16 16:38","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2651417551","market":"us","top_or_hot":-1,"title":"首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】</b>首药控股公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】</b>首药控股公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4503","symbol_name":"景林资产持仓","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2651417551","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651417551","pubTimestamp":1784191092,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】首药控股公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，S","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4503":"景林资产持仓","XTN":"SPDR S&P Transportation ETF","BK4077":"互动媒体与服务","ALK":"阿拉斯加航空集团有限公司","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","SY":"新氧","BK4500":"航空公司","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4008":"航空公司","BK4563":"昨日强势股"},"translate_title":"First Drug Holdings: SY-12321 capsule single drug clinical trial application in ALK-positive advanced solid tumors approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1.5,"ALK":1.5,"BMED":1.5,"SY":1.5,"XTN":0.6},"content_text":"【首药控股：SY-12321胶囊单药在ALK阳性晚期实体瘤的临床试验申请获得批准】首药控股公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，作为第四代ALK抑制剂候选药物，SY-12321胶囊单药在间变性淋巴瘤激酶阳性晚期实体瘤的临床试验申请获得批准。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651417551","isCrawlerRequest":true}